Comparing Hybrid and Catheter Ablation Treatments for Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy

What this Trial Is About

Researchers are evaluating the rhythm control effects in patients with hypertrophic non-obstructive cardiomyopathy who have non-paroxysmal atrial fibrillation. The study aims to compare if a combined hybrid ablation approach, involving both thoracoscopic epicardial and catheter endocardial ablation, can better manage rhythm control than catheter ablation alone in these patients. This clinical trial is sponsored by the China National Center for Cardiovascular Diseases and includes 66 eligible participants. Participants will be randomly assigned to one of two groups. One group will receive a combination of thoracoscopic epicardial ablation and catheter endocardial ablation simultaneously, known as hybrid ablation. The other group will receive catheter endocardial ablation only. The main treatment period will assess outcomes over a one-year timeframe following the procedures. Throughout the study, participants will be monitored for freedom from atrial arrhythmias for 3 to 12 months without antiarrhythmic drugs, which is the primary outcome. Secondary outcomes include mortality rates, incidence of stroke or embolism, rehospitalization related to heart conditions, and rhythm control with antiarrhythmic drugs within the same period. Participants will undergo follow-ups and evaluations to track these outcomes and ensure safety and adherence to study requirements.

Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy